Good find, @vinn - one of the advantages of allogeneic cells is you can harvest them from young donors to get the maximum effect, since as we age our own stem cells are less potent, hence one of the limitations of autologous therapy.
Also, in the back of my mind I recalled that part of the Cephalon deal was neuro diseases - and sure enough, MSB has a granted US patent for MS (US 10,206,951)!!
We don't hear anything any more about Parkinsons or Alzheimers - but these two at least were originally licensed to Cephalon, so I'd expect MSB has a fair bit of data on them.
Cell Therapy News/Articles, page-366
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
0.010(0.67%) |
Mkt cap ! $1.113B | |||
| Open | High | Low | Value | Volume |
| $1.51 | $1.52 | $1.43 | $5.466M | 3.709M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 64735 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.50 | 5178 | 4 |
View Market Depth
| Last trade - 15.39pm 22/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
